Mabwell (Shanghai) Bioscience Balance Sheet Health
Financial Health criteria checks 4/6
Mabwell (Shanghai) Bioscience has a total shareholder equity of CN¥2.4B and total debt of CN¥1.7B, which brings its debt-to-equity ratio to 72.6%. Its total assets and total liabilities are CN¥4.6B and CN¥2.2B respectively.
Key information
72.6%
Debt to equity ratio
CN¥1.74b
Debt
Interest coverage ratio | n/a |
Cash | CN¥1.80b |
Equity | CN¥2.40b |
Total liabilities | CN¥2.25b |
Total assets | CN¥4.64b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688062's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥1.1B).
Long Term Liabilities: 688062's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 688062 has more cash than its total debt.
Reducing Debt: 688062's debt to equity ratio has increased from 0% to 72.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688062 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688062 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.